Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP) -- Ignore unavailable to you. Want to Upgrade?

To: David Wolfson who wrote (1081)	10/29/1998 10:32:00 AM
From: SAM-DAN	Read Replies (1) \| Respond to of 1501

New management.Clean House ,strong backers.No wonder they replaced old Board.After this poor PR passes , fundamentals will revive the company.

To: David Wolfson who wrote (1081)	11/2/1998 5:47:00 PM
From: Chuca Marsh	Read Replies (2) \| Respond to of 1501

Hey, doc, here is some NATURAL news, what is your analyst-ation say for us threaders: Natural is GOOD- Your thoughts? My posts talked about this thought: Beverly Hills 90210/Papua New Guinea IPL 576,092/ Inveresk Research, Edinburgh, Scotland 000000000#1/ IZP not a zipo hope out by Shots and Mac Beath( an "a" for my Scot Heritage added!) Outta a Spota @ Zip Code Revision-80 cents per share he betta( beta factor) get the results a Shotas/ kappa factor X or it is C for I: Return-Path: newsout@canada-stockwatch.com From: newsout@canada-stockwatch.com Date: Mon, 02 Nov 1998 14:09:17 -0800 Subject: Stockwatch: Inflazyme Pharmaceuticals Ltd - News Release Toxicology studies for asthma compound Inflazyme Pharmaceuticals Ltd IZP Shares issued 24,997,493 Oct 30 close $0.41 Mon 2 Nov 98 News Release Mr. Ian McBeath reports Inflazyme has received a sufficient quantity of its lead asthma product IPL 576,092 to complete its extended preclinical toxicology program and begin clinical trials. The company expects IPL 576,092 to enter 14 day animal toxicology studies in December with Inveresk Research, Edinburgh, Scotland. The company anticipates, subject to a positive outcome from its toxicology program, that it will be possible to commence phase I human clinical trials during the first half of 1999. Until May of this year, the company had been experiencing difficulties with the chemistry of its original molecule being progressed. At that time a decision was taken to progress a backup analogue, IPL 576,092, which appeared to be easier to synthesize. The company undertook an accelerated preclinical program and confirmed that it should take forward IPL 576,092 as the lead molecule. Production of this material enables the company to move forward rapidly to the next stage in the development of what may be a new treatment for asthma. IPL 576,092 is a molecule from the sea, having been developed from a natural compound isolated from a sea sponge obtained from the ocean off the coast of Papua New Guinea. In animal models of asthma it displays efficacy comparable to that seen with inhaled glucocorticoids, but without the side effects associated with these products. Inflazyme is developing IPL 576,092 as a potential oral alternative to inhaled glucocorticoids. The options granted to Ian McBeath in May 1998 on the commencement of his directorship, were replaced this month with employee options exercisable at 80 cents per share. canada-stockwatch.com